Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

ARWR

Live52w high -10.1%

Annual Quarterly

Core line items from ARWR's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Entity: ARROWHEAD PHARMACEUTICALS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-05	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Annual 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$54.18M	$337.77M	$264.03M	$829.45M	$572.98M
Operating Income	Not available	$-100.45M	$40.81M	$98.35M	$54.24M
Net Income	Not available	$-101.92M	$30.81M	$-1.63M	$22.12M
EPS (Diluted)	$-1.39	$-0.73	$0.22	$-0.01	$0.17
Total Assets	Not available	$2.27B	$1.60B	$1.39B	$1.38B
Total Liabilities	Not available	Not available	Not available	Not available	Not available
Cash & Equivalents	Not available	$188.52M	$201.64M	$226.55M	$129.79M
Free Cash Flow OCF − CapEx	Not available	$93.21M	$11.33M	$156.89M	$143.88M
Shares Outstanding	Not available	140.57M	137.39M	135.70M	138.14M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from ARWR's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -10.1%

Entity: ARROWHEAD PHARMACEUTICALS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-05	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Annual 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$54.18M	$337.77M	$264.03M	$829.45M	$572.98M
Operating Income	Not available	$-100.45M	$40.81M	$98.35M	$54.24M
Net Income	Not available	$-101.92M	$30.81M	$-1.63M	$22.12M
EPS (Diluted)	$-1.39	$-0.73	$0.22	$-0.01	$0.17
Total Assets	Not available	$2.27B	$1.60B	$1.39B	$1.38B
Total Liabilities	Not available	Not available	Not available	Not available	Not available
Cash & Equivalents	Not available	$188.52M	$201.64M	$226.55M	$129.79M
Free Cash Flow OCF − CapEx	Not available	$93.21M	$11.33M	$156.89M	$143.88M
Shares Outstanding	Not available	140.57M	137.39M	135.70M	138.14M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.